[177Lu]-PSMA-617 (Pluvicto®) was recently FDA approved for treatment of metastatic castrate resistant prostate cancer along with its corresponding equivalent imaging agent, [68Ga]-PSMA. This evidence concerns the gene FOLH1 and prostate cancer.